Objective:To evaluate the efficacy and safety of XuanFei TongFu method in the treatment of sepsis.Methods:The relevant literatures on the treatment of sepsis by Xuanfei Tongfu method,published by PubMed,Medline and th...Objective:To evaluate the efficacy and safety of XuanFei TongFu method in the treatment of sepsis.Methods:The relevant literatures on the treatment of sepsis by Xuanfei Tongfu method,published by PubMed,Medline and the Cochrane library,CNKI,WEIPU Database,WANFANG Database until December 2019 were searched by computer.Revman 5.3 was used to analyze the relevant literatures that met the inclusion and exclusion criteria,and to evaluate the influence of Xuanfei Tongfu method on gastrointestinal function,adverse reactions of gastrointestinal,28 day mortality.Results:a total of 17 randomized controlled clinical trials(RCTS)involving a total of 984 patients were included.Xuanfei Tongfu decoction combined with the control group can improve intestinal function.Xuanfei Tongfu decoction can reduce gastrointestinal adverse reactions,but there is no statistical significance,and reducing mortality of 28 days(RR=0.64,95%CI(0.42,0.99),P=0.04),reducing the APACHEⅡ[SMD=-0.90,95%CI(-1.49,-0.31),P=0.0003],reducing of Il-6[SMD=-0.36,95%CI(-0.62,-0.1),P=0.007],and improving IL-10 were all better than the control group,the difference was statistically significant.Conclusion:The method of Xuanfei Tongfu can enhance the gastrointestinal function,reduce the gastrointestinal adverse reactions,and improve the prognosis of sepsis patients.It may be achieved by regulating the body's immune inflammatory response.展开更多
目的:观察宣肺通腑汤治疗中老年重症肺炎合并胃肠功能障碍的疗效及对胃肠功能的保护作用及对炎症因子的影响。方法:将104例符合要求的患者随机分为对照组和观察组各52例。对照组给予抗感染治疗、抗炎治疗、对症治疗及支持治疗,给予枸...目的:观察宣肺通腑汤治疗中老年重症肺炎合并胃肠功能障碍的疗效及对胃肠功能的保护作用及对炎症因子的影响。方法:将104例符合要求的患者随机分为对照组和观察组各52例。对照组给予抗感染治疗、抗炎治疗、对症治疗及支持治疗,给予枸橼酸莫沙必利口服溶液,10 m L/次,3次/d,口服;双歧杆菌三联活菌散,2 g/次,3次/d,口服。观察组在对照组治疗的基础上给予宣肺通腑汤,1剂/d。两组疗程均连续治疗14 d。记录治疗前后CURB65,SMART-COP,临床肺部感染评分(CPIS),中医证候评分、胃肠功能障碍(GIDF),急性病生理和长期健康Ⅱ评分(APACHEⅡ)和多器官功能障碍综合征(MODS)评分,检测治疗前后血清胃动素(MTL),胃泌素(GAS),D-乳酸,二胺氧化酶(DAO),降钙素原(PCT),白细胞介素-6(IL-6),IL-8,肿瘤坏死因子-α(TNF-α)水平;记录ICU病死率(2周内),ICU住院日、机械通气时间。结果:观察组患者临床疗效愈显率为59.62%,高于对照组愈显率38.46%(χ^2=4.6564,P〈0.05);观察组机械通气时间和ICU住院日均短于对照组(P〈0.01),观察组ICU病死率11.54%,低于对照组病死率15.38%,组间比较差异无统计学意义;观察组患者CURB65,SMART-COP,CPIS,中医证候,GIDF,APACHEⅡ和MODS评分均低于对照组(P〈0.01);观察组血清GAS,D-乳酸和DAO水平均低于对照组,MTL水平高于对照组(P〈0.01);观察组患者血清PCT,TNF-α,IL-6和IL-8水平均低于对照组(P〈0.01)。结论:在西医常规治疗的基础上,宣肺通腑汤辅助治疗重症肺炎合并GIDF患者,可控制临床症状,调节胃肠激素,促进肠黏膜屏障修复和胃肠功能恢复,抑制炎症反应,减轻病情程度,缩短了疾病的愈合时间。展开更多
基金Key R&D Plan of Shaanxi Provincial Department of Science and Technology(No.2017ZDXM-SF-109)。
文摘Objective:To evaluate the efficacy and safety of XuanFei TongFu method in the treatment of sepsis.Methods:The relevant literatures on the treatment of sepsis by Xuanfei Tongfu method,published by PubMed,Medline and the Cochrane library,CNKI,WEIPU Database,WANFANG Database until December 2019 were searched by computer.Revman 5.3 was used to analyze the relevant literatures that met the inclusion and exclusion criteria,and to evaluate the influence of Xuanfei Tongfu method on gastrointestinal function,adverse reactions of gastrointestinal,28 day mortality.Results:a total of 17 randomized controlled clinical trials(RCTS)involving a total of 984 patients were included.Xuanfei Tongfu decoction combined with the control group can improve intestinal function.Xuanfei Tongfu decoction can reduce gastrointestinal adverse reactions,but there is no statistical significance,and reducing mortality of 28 days(RR=0.64,95%CI(0.42,0.99),P=0.04),reducing the APACHEⅡ[SMD=-0.90,95%CI(-1.49,-0.31),P=0.0003],reducing of Il-6[SMD=-0.36,95%CI(-0.62,-0.1),P=0.007],and improving IL-10 were all better than the control group,the difference was statistically significant.Conclusion:The method of Xuanfei Tongfu can enhance the gastrointestinal function,reduce the gastrointestinal adverse reactions,and improve the prognosis of sepsis patients.It may be achieved by regulating the body's immune inflammatory response.
文摘目的:观察宣肺通腑汤治疗中老年重症肺炎合并胃肠功能障碍的疗效及对胃肠功能的保护作用及对炎症因子的影响。方法:将104例符合要求的患者随机分为对照组和观察组各52例。对照组给予抗感染治疗、抗炎治疗、对症治疗及支持治疗,给予枸橼酸莫沙必利口服溶液,10 m L/次,3次/d,口服;双歧杆菌三联活菌散,2 g/次,3次/d,口服。观察组在对照组治疗的基础上给予宣肺通腑汤,1剂/d。两组疗程均连续治疗14 d。记录治疗前后CURB65,SMART-COP,临床肺部感染评分(CPIS),中医证候评分、胃肠功能障碍(GIDF),急性病生理和长期健康Ⅱ评分(APACHEⅡ)和多器官功能障碍综合征(MODS)评分,检测治疗前后血清胃动素(MTL),胃泌素(GAS),D-乳酸,二胺氧化酶(DAO),降钙素原(PCT),白细胞介素-6(IL-6),IL-8,肿瘤坏死因子-α(TNF-α)水平;记录ICU病死率(2周内),ICU住院日、机械通气时间。结果:观察组患者临床疗效愈显率为59.62%,高于对照组愈显率38.46%(χ^2=4.6564,P〈0.05);观察组机械通气时间和ICU住院日均短于对照组(P〈0.01),观察组ICU病死率11.54%,低于对照组病死率15.38%,组间比较差异无统计学意义;观察组患者CURB65,SMART-COP,CPIS,中医证候,GIDF,APACHEⅡ和MODS评分均低于对照组(P〈0.01);观察组血清GAS,D-乳酸和DAO水平均低于对照组,MTL水平高于对照组(P〈0.01);观察组患者血清PCT,TNF-α,IL-6和IL-8水平均低于对照组(P〈0.01)。结论:在西医常规治疗的基础上,宣肺通腑汤辅助治疗重症肺炎合并GIDF患者,可控制临床症状,调节胃肠激素,促进肠黏膜屏障修复和胃肠功能恢复,抑制炎症反应,减轻病情程度,缩短了疾病的愈合时间。